智飞生物：公司自主产品流感病毒裂解疫苗获得药品注册证书

Core Viewpoint - The company Zhifei Biological's subsidiary has received a drug registration certificate for its influenza virus split vaccine, which is aimed at individuals aged 32 and above to prevent infections caused by the influenza virus [1] Group 1: Product Development - The newly approved trivalent influenza vaccine is one of the main products for influenza prevention both domestically and internationally [1] - The company has a diverse range of influenza vaccine products, including an already approved quadrivalent influenza virus split vaccine and a trivalent influenza virus split vaccine that is currently in clinical trials [1] Group 2: Market Position - The vaccine series covers all age groups, indicating a comprehensive approach to influenza prevention [1] - The company is expanding its product offerings with various types of influenza vaccines, enhancing its market presence [1]